Original'nyy atorvastatin v kompleksnoy terapii bol'nykh s ateroskleroticheskim porazheniem brakhiotsefal'nykh arteriy

Cover Page
  • Authors: Rudenko A.V1, Rudenko B.A2
  • Affiliations:
    1. ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России, Москва
    2. ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России, Москва
  • Issue: Vol 16, No 10 (2014)
  • Pages: 126-130
  • Section: Articles
  • URL: https://ogarev-online.ru/2075-1753/article/view/94292
  • ID: 94292

Cite item

Full Text

Abstract

Гиполипидемическая терапия занимает центральное звено в комплексной медикаментозной профилактике атеросклероза и его осложнений. Один из наиболее известных и широко применяемых препаратов этой группы оригинальный аторвастатин - Липримар® доказал свою высокую эффективность как для первичной профилактики ишемической болезни сердца - ИБС (когда у пациента имеются только факторы риска ее развития), так и для вторичной (замедление прогрессирования сердечно-сосудистой патологии и снижение риска осложнений). Целью настоящей работы является анализ роли и места статинов (и, в частности, аторвастатина) в профилактике инсульта у больных с атеросклеротическим поражением брахиоцефальных артерий.

About the authors

A. V Rudenko

ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России, Москва

B. A Rudenko

ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России, Москва

References

  1. Sever P.S, Dahlöf B, Poulter N.R et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58
  2. Shepherd J, Barter P, Carmena R et al. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes. The Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-6.
  3. Colhoun H.M, Betteridge D.J, Durrington P.N et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo - controlled trial. Lancet 2004; 364: 685-96.
  4. Schulz R. Pleiotropic effects of statins: acutely good, but chronically bad? J Am Coll Cardiol 2005; 45: 1292-4.
  5. Sanguigni V, Pignatelli P, Lenti L et al. Short - term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111: 412-9.
  6. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
  7. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003; 91 (Suppl.): 4B-8B.
  8. Pasceri V, Patti G, Nusca A et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110 (6): 674-8.
  9. Patti G, Pasceri V, Colonna G et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49 (12): 1272-8.
  10. Di Sciascio G, Patti G, Pasceri V et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatinfor Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009; 54 (6): 558-65.
  11. Kim J.S, Kim J, Choi D et al. Efficacy of high - dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATINSTEMI trial. JACC Cardiovasc Int 2010; 3 (3): 332-9.
  12. Briguori C, Visconti G, Focaccio A et al. Novel Approaches for Preventing or Limiting Events (Naples) II Trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54: 2157-63.
  13. Patti G, Cannon C.P, Murphy S.A et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient - level meta - analysis of 13 randomized studies. Circulation 2011; 123: 1622-32.
  14. Furie K.L, Kasner S.E, Adams R.J et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42 (1): 227-76.
  15. Writing Group Members, Roger V.L, Go A.S et al. Heart disease and stroke statistics - 2012 update. Circulation 2012; 125: e2-e220.
  16. De Weerd M, Greving J.P, De Jong A.W et al. Prevalence of asymptomatic carotid artery stenosis according to age and sex: systematic review and metaregression analysis Stroke. J Cereb Circul 2009; 40: 1105-13.
  17. Sander D.D.C, Eckstein H.H et al. S3 Guideline Extracranial Carotid Stenosis, chapter 6: Epidemiology. Gefässchirurgie 2012; 17: 497-501.
  18. Nicolaides A.N, Kakkos S.K, Griffin M et al. Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study European Journal of Vascular and Endovascular Surgery. Official J Eur Soc Vasc Surg 2005; 30: 275-84.
  19. Stein J.H, Korcarz C.E, Hurst R.T et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J Am Soc Echocardiogr 2008; 21: 93-111.
  20. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke 2005; 36: 2764-72.
  21. Brott T.G, Halperin J.L, Abbara S et al. АSA/ACCF/AHA/AANN/ AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the management of patients with extracranial carotid and vertebral artery disease. J Am Coll Cardiol 2011; 57: 1002-44.
  22. Tendera M, Aboyans V, Bartelink M.L et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851-906.
  23. Ricotta J.J, Aburahma A, Ascher E et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. J Vasc Surg 2011; 54: e1-e31.
  24. Negre-Aminou P, Van Vliet A.K, Van Erck M et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345 (3): 259-68.
  25. Hinoi T, Matsuo S, Tadehara F et al. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. Am J Cardiol 2005; 96: 89-91.
  26. Wassmann S, Faul A, Hennen B et al. Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 2003; 93: e98-e103.
  27. Laufs U, Wassmann S, Hilgers S et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88 (11): 1306-7.
  28. Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999; 82 (5): 1390-4.
  29. Nissen S.E, Tuzcu E.M, Schoenhagen P et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. A Randomized Controlled Trial. JAMA 2004; 291: 1071-80.
  30. Bonnet J, Mc Pherson R, Tedgui A et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high - sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 2008; 30 (12): 2298-313.
  31. Ridker P.M, Cannon C.P, Morrow D et al. For PROVE IT-TIMI22 Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352 (1): 20-8.
  32. Wilson P.W.F, Pencina M, Jacques P et al. C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1: 92-7.
  33. Shiomi M, Ito T, Hirouchi Y, Enomoto M. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis 2001; 157: 75-84.
  34. Martin-Ventura J.L, Blanco-Colio L.M, Gomez-Hernandez A et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005; 36: 1796-800.
  35. Tang T.Y, Howarth S.P, Miller S.R et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxideenhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009; 53 (22): 2039-50.
  36. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high - grade carotid stenosis. N Engl J Med 1995; 325: 445-53.
  37. Michael D, Walker M.D, John R et al. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. J Am Med Assoc 1995; 273: 1421-8.
  38. Mas J.L, Chatellier G, Beyssen B et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355: 1660-71.
  39. Eckstein H.H, Ringleb P, Allenberg J.R et al. Results of the Stent - Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol 2008; 7 (10): 893-902.
  40. Gurm H.S, Yadav J.S, Fayad P et al. SAPPHIRE Investigators, Long - term results of carotid stenting vs endarterectomy in high - risk patients. N Engl J Med 2008; 358 (15): 1572-9.
  41. Mantese V.A, Timaran C.H, Chiu D et al. CREST Investigators The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): stentingversus carotid endarterectomy for carotid disease. Stroke 2010; 41 (Suppl. 10): S31-4.
  42. Gröschel K, Ernemann U, Schulz JB et al. Statin therapy at carotid angioplasty and stent placement: effect on procedure - related stroke, myocardial infarction, and death. Radiology 2006; 240: 145-51.
  43. Patti G, Tomai F, Melfi R et al. Strategies of Clopidogrel Load and Atorvastatin Reload to Prevent Ischemic Cerebral Events in Patients Undergoing Protected Carotid Stenting: Results of the Randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) Study. J Am Coll Cardiol 2013; 61 (13): 1379-87.
  44. Ifergan I, Wosik K, Cayrol R et al. Statins reduce human blood - brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 2006; 60: 45-55.
  45. Yang D, Knight R.A, Han Y et al. Vascular recovery promoted by atorvastatin and simvastatin after experimental intracerebral hemorrhage: magnetic resonance imaging and histological study. J Neurosurg 2011; 114: 1135-42.
  46. Jung K.H, Chu K, Jeong S.W et al. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 2004; 35: 1744-9.
  47. Endres M, Laufs U, Huang Z et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).